Abstract

PurposeTo investigate predictors of testicular response and non-reproductive outcomes (height, body proportions) after gonadotropin-induced puberty in congenital hypogonadotropic hypogonadism (CHH).DesignA retrospective analysis of the puberty induction in CHH male patients, undergoing an off-label administration of combined gonadotropin (FSH and hCG).MethodsClinical and hormonal evaluations before and during gonadotropin stimulation in 19 CHH patients genotyped by Targeted Next Generation Sequencing for CHH genes; 16 patients underwent also semen analysis after gonadotropins.ResultsA lesser increase in testicular volume after 24 months of induction was significantly associated with: (I) cryptorchidism; (II) a positive genetic background; (III) a complete form of CHH. We found no significant correlation with the cumulative dose of hCG administered in 24 months. We found no association with the results of semen analyses, probably due to the low numerosity. Measures of body disproportion (eunuchoid habitus and difference between adult and target height: deltaSDSth), were significantly related to the: (I) age at the beginning of puberty induction; (II) duration of growth during the induction; (III) initial bone age. The duration of growth during induction was associated with previous testosterone priming and to partial forms of CHH.ConclusionsThis study shows that a strong genetic background and cryptorchidism, as indicators of a complete GnRH deficiency since intrauterine life, are negative predictors of testicular response to gonadotropin stimulation in CHH. Body disproportion is associated with a delay in treatment and duration of growth during the induction, which is apparently inversely related to previous androgenization.

Highlights

  • congenital hypogonadotropic hypogonadism (CHH) is a rare disease with a strong genetic background, which leads to absent or incomplete puberty due to insufficient hypothalamic-pituitary stimulation of the gonads [1,2,3]

  • We found no significant differences in Bi-testicular volume (BTV) at 18 or 24 months of gonadotropin-mediated pubertal induction according to previous testosterone priming or pre-treatment with FSH (p = 0.2–0.38)

  • We studied all the clinical parameters that could predict a different response to gonadotropin treatment, both regarding reproductive and non-reproductive outcomes

Read more

Summary

Introduction

CHH is a rare disease with a strong genetic background, which leads to absent (complete forms) or incomplete (partial forms) puberty due to insufficient hypothalamic-pituitary stimulation of the gonads [1,2,3]. Data concerning the gonadotropin-mediated pubertal induction are scarce, as the available studies are all characterized by low numerosity, heterogeneous age of the enrolled patients, mixed underlying causes (series composed of CHH and combined pituitary hormone deficiencies, Journal of Endocrinological Investigation (2021) 44:2445–2454. The extremely different results obtained in all these studies are not surprising. Two of four randomized clinical trials were not performed in adults and did not evaluate genetics or nonreproductive outcomes of the treatment [13,14,15,16]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call